Refining the Optimal First Treatment for Pediatric Breast Abscesses

Kayla B. Briggs

Children's Mercy Hospital

May 10th, 11:30 AM - 1:30 PM

Let us know how access to this publication benefits you

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/researchdays

Part of the Bacteria Commons, Pediatrics Commons, Skin and Connective Tissue Diseases Commons, Surgery Commons, and the Surgical Procedures, Operative Commons

Briggs, Kayla B., "Refining the Optimal First Treatment for Pediatric Breast Abscesses" (2021). Research Days. 15.
https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2021/researchday1/15

This Poster Presentation is brought to you for free and open access by the Conferences and Events at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.
Further Examining the Optimal Treatment for Pediatric Breast Abscess

Kayla B. Briggs MD, Charlene Dekonenko MD, James A. Fraser MD, Wendy Jo Svetanoff MD MPH, Tolulope A. Oyetunji MD MPH, Jason D. Fraser MD

Methods

• Single-institution, retrospective review
• Patients <18 years old with breast abscess
• Stratified by UTND or previously treated, not spontaneously draining (PTND)
• Primary outcome: persistent disease requiring further treatment

Results

• 114 patients met inclusion criteria
  • 96 UTND
  • 18 PTND
• Patients 1st treated at outside hospitals (OSH) were more likely to use antibiotics alone as primary therapy (100% vs. 47%, p<0.001)
  • Persistent disease more common in those treated with abx 1st at OSH vs. abx 1st at CMH
• 11/18 children treated first at OSH required treatment for persistent disease (73% needle aspiration, 27% incision and drainage)
• TMP-SMX used most at OSH (50%) vs. Clindamycin at CMH (71%, p<0.01)

Conclusion

Antibiotic therapy, when properly chosen, remains a safe first-line treatment of pediatric breast abscesses.